Figures & data
Figure 1. Model of oral candidiasis and the immune system’s response for clearing Candida species. In response to Candida species, macrophages are activated, which recruit CD4+T cells or TH17 cells through various cytokines, in order to activate neutrophils or release β-defensin to clear Candida infection.
Figure 2. IL-17 inhibitors, attachment sites, and mechanism of action. Secukinumab and ixekizumab interact with IL-17A/A, and A/F, bimekizumab attached to IL-17A/A, A/F, and F/F, and brodalumab inhibit IL-17A, IL-17C, and IL-17E.
Figure 3. Monitoring of candidiasis in patients treated with IL-17 inhibitors.
Figure 4. Clinical presentation, diagnosis and treatment of candidiasis associated with IL-17 inhibitors.
